These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19646870)

  • 1. Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.
    Patel HK; Grotzfeld RM; Lai AG; Mehta SA; Milanov ZV; Chao Q; Sprankle KG; Carter TA; Velasco AM; Fabian MA; James J; Treiber DK; Lockhart DJ; Zarrinkar PP; Bhagwat SS
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5182-5. PubMed ID: 19646870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
    Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations.
    Nishiyama U; Yoshino T; Ozai M; Yoshioka R; Fujisawa M; Ogasawara Y; Kitahori M; Yoshioka E; Kubo K; Komeno Y; Kurokawa M; Ogawa S; Chiba S; Osawa T; Kuwaki T; Hirai H; Miwa A
    Leuk Res; 2006 Dec; 30(12):1541-6. PubMed ID: 16603240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.
    Chao Q; Sprankle KG; Grotzfeld RM; Lai AG; Carter TA; Velasco AM; Gunawardane RN; Cramer MD; Gardner MF; James J; Zarrinkar PP; Patel HK; Bhagwat SS
    J Med Chem; 2009 Dec; 52(23):7808-16. PubMed ID: 19754199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
    Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
    J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Hsu JT; Yeh TK; Yen SC; Chen CT; Hsieh SY; Hsu T; Lu CT; Chen CH; Chou LH; Chiu CH; Chang YI; Tseng YJ; Yen KR; Chao YS; Lin WH; Jiaang WT
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4654-9. PubMed ID: 22726931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
    Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
    J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
    Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
    Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
    Davies RJ; Pierce AC; Forster C; Grey R; Xu J; Arnost M; Choquette D; Galullo V; Tian SK; Henkel G; Chen G; Heidary DK; Ma J; Stuver-Moody C; Namchuk M
    J Med Chem; 2011 Oct; 54(20):7184-92. PubMed ID: 21970471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors.
    Chen CH; Lee O; Yao CN; Chuang MY; Chang YL; Chang MH; Wen YF; Yang WH; Ko CH; Chou NT; Lin MW; Lai CP; Sun CY; Wang LM; Chen YC; Hseu TH; Chang CN; Hsu HC; Lin HC; Chang YL; Shih YC; Chou SH; Hsu YL; Tseng HW; Liu CP; Tu CM; Hu TL; Tsai YJ; Chen TS; Lin CL; Chiou SJ; Liu CC; Hwang CS
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6129-32. PubMed ID: 20833039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
    Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
    J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antiproliferative activity of novel diaryl ureas possessing a 4H-pyrido[1,2-a]pyrimidin-4-one group.
    Yao P; Zhai X; Liu D; Qi BH; Tan HL; Jin YC; Gong P
    Arch Pharm (Weinheim); 2010 Jan; 343(1):17-23. PubMed ID: 19927308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
    Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
    Schroeder GM; An Y; Cai ZW; Chen XT; Clark C; Cornelius LA; Dai J; Gullo-Brown J; Gupta A; Henley B; Hunt JT; Jeyaseelan R; Kamath A; Kim K; Lippy J; Lombardo LJ; Manne V; Oppenheimer S; Sack JS; Schmidt RJ; Shen G; Stefanski K; Tokarski JS; Trainor GL; Wautlet BS; Wei D; Williams DK; Zhang Y; Zhang Y; Fargnoli J; Borzilleri RM
    J Med Chem; 2009 Mar; 52(5):1251-4. PubMed ID: 19260711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.
    Zimmermann K; Wittman MD; Saulnier MG; Velaparthi U; Sang X; Frennesson DB; Struzynski C; Seitz SP; He L; Carboni JM; Li A; Greer AF; Gottardis M; Attar RM; Yang Z; Balimane P; Discenza LN; Lee FY; Sinz M; Kim S; Vyas D
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1744-8. PubMed ID: 20153189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer.
    Chen Z; Venkatesan AM; Dehnhardt CM; Dos Santos O; Delos Santos E; Ayral-Kaloustian S; Chen L; Geng Y; Arndt KT; Lucas J; Chaudhary I; Mansour TS
    Bioorg Med Chem Lett; 2009 Sep; 19(17):4980-3. PubMed ID: 19640711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3.
    Li WW; Chen JJ; Zheng RL; Zhang WQ; Cao ZX; Yang LL; Qing XY; Zhou LX; Yang L; Yu LD; Chen LJ; Wei YQ; Yang SY
    ChemMedChem; 2010 Apr; 5(4):513-6. PubMed ID: 20140937
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors.
    Ishida H; Isami S; Matsumura T; Umehara H; Yamashita Y; Kajita J; Fuse E; Kiyoi H; Naoe T; Akinaga S; Shiotsu Y; Arai H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5472-7. PubMed ID: 18835166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors.
    Gaul MD; Xu G; Kirkpatrick J; Ott H; Baumann CA
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4861-5. PubMed ID: 17611106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.